Rothschild Investment Corp Vir Biotechnology, Inc. Transaction History

Rothschild Investment Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 18, 2023	SELL	$23.2 - $27.29 $78,880 - $92,786	-3,400 Reduced 12.04%	24,850 $610,000
Q1 2023 Apr 24, 2023	SELL	$22.26 - $30.85 $6,678 - $9,255	-300 Reduced 1.05%	28,250 $657,000
Q4 2022 Jan 19, 2023	SELL	$19.96 - $28.22 $101,796 - $143,922	-5,100 Reduced 15.16%	28,550 $723,000
Q3 2022 Oct 21, 2022	SELL	$18.26 - $31.1 $27,390 - $46,650	-1,500 Reduced 4.27%	33,650 $649,000
Q2 2022 Jul 12, 2022	SELL	$19.08 - $26.7 $40,068 - $56,070	-2,100 Reduced 5.64%	35,150 $895,000
Q1 2022 Apr 18, 2022	SELL	$21.19 - $40.01 $27,547 - $52,013	-1,300 Reduced 3.37%	37,250 $958,000
Q3 2021 Oct 12, 2021	SELL	$34.9 - $54.54 $69,800 - $109,080	-2,000 Reduced 4.93%	38,550 $1.68 Million
Q2 2021 Jul 19, 2021	SELL	$38.75 - $51.0 $34,875 - $45,900	-900 Reduced 2.17%	40,550 $1.92 Million
Q1 2021 Apr 15, 2021	BUY	$26.34 - $83.07 $488,607 - $1.54 Million	18,550 Added 81.0%	41,450 $2.13 Million
Q4 2020 Jan 25, 2021	BUY	$25.51 - $43.38 $258,926 - $440,307	10,150 Added 79.61%	22,900 $613,000
Q3 2020 Oct 22, 2020	BUY	$28.28 - $53.6 $360,570 - $683,400	12,750 New	12,750 $438,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $991M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Rothschild Investment Corp , based on Form 13F filings with the SEC.

Stay updated on Rothschild Investment Corp with notifications on news.